Sector News

GSK to pocket $890 mln by halving stake in S.African drugmaker

March 14, 2015
Life sciences
(Reuters) – GlaxoSmithKline has decided to take profits in Aspen Pharmacare by halving its stake in the South African drugmaker, following a long investment in the firm.
 
The sale will be conducted through a share placing at a discount to the market price, which is expected to raise around $890 million.
 
Britain’s biggest drugmaker said on Thursday it would remain a 6.2 percent shareholder in Aspen and it had undertaken not to sell any more shares in the South African group for 180 days.
 
A source familiar with the matter said a price range of 365 to 385 rand per share had been set for the placement, representing a discount of 5.3 to 10.2 percent to Aspen’s closing price on Thursday.
 
The share sale is being run by Citi and UBS.
 
Simon Dingemans, GSK’s chief financial officer, said the disposal would help give his company flexibility to invest in new opportunities in the wake of a $20 billion-plus asset swap transaction with Novartis.
 
“As we continue to reshape the group around our core franchises and drive the benefits from the Novartis transaction, optimising our financial flexibility to invest behind these priorities is key,” he said in a statement.
 
“As a result we have decided now is the right time to realise further value from this successful relationship. We continue to believe in the strategy of Aspen and we remain committed to working together in the future.”
 
GSK said that the net profit on the disposal would not be included in core operating profit and core earnings in 2015, and GSK would no longer account for Aspen as an associate. (Reporting by Freya Berry, Vikram Subhedar and Ben Hirschler; Editing by Pamela Barbaglia, Greg Mahlich)

comments closed

Related News

May 27, 2023

Positive opinion for Novo Nordisk’s Sogroya

Life sciences

Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has provided a positive opinion for the company’s Sogroya therapy. The once-weekly treatment – also known as somapacitan – is for the replacement of endogenous growth hormone (GH) in aged children three years and older.

May 27, 2023

Medtronic acquires insulin patch pump maker EOFlow for $738M amid new MiniMed rollout

Life sciences

Medtronic is set to acquire EOFlow, the South Korea-based maker of an insulin patch pump. In its announcement of the deal Thursday, Medtronic suggested that integrating the tubeless device with its own continuous glucose monitors and meal-detection algorithm could create a new closed-loop system for largely hands-off diabetes management.

May 27, 2023

Apnimed cracks sleep apnea puzzle, hits primary goal in phase 2 study

Life sciences

Apnimed started the year by bagging nearly $80 million in extended series C funds and the momentum has kept up, with the sleep-apnea-focused biotech nailing its goals in a phase 2 study. “For those who cannot tolerate current treatments, AD109 has the potential to be a convenient, oral pill that could improve people’s quality of life both at night and during the day.”

How can we help you?

We're easy to reach